Delivery Order SPE2DB22D3004-SPE2DB25FRP30
Award Date 7/22/25
Potential Completion Date 8/12/25
Potential Value $3.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector prefilled syringes. This competitive award, valued at $3,188.32 with firm fixed pricing, is scheduled for completion by August 18, 2025. The contract represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. As a pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $3,188.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for Xolair 300 mg/2 ml auto-injector units, with completion targeted for August 11, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered from AmerisourceBergen's...
- The Defense Logistics Agency awarded a $11,159.12 delivery order to AmerisourceBergen Drug Corp for the supply of Xolair 300 mg/2 mL autoinjectors on August 5, 2025, with completion targeted for August 26, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody used to treat moderate-to-severe asthma and chronic urticaria,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $3,188.32. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a single delivery order issued under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16, with completion scheduled for August 18, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xolair (omalizumab) is a monoclonal antibody therapeutic used primarily for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 20, 2025, for the supply of XOLAIR 300 MG/2 ML Auto-Injector at a ceiling value of $6,376.64. This firm fixed-price delivery order, which is expected to be completed by July 14, 2025, represents a non-set-aside competitive award. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. XOLAIR (omalizumab) is a monoclonal antibody therapy...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xolair 300 mg/2 ml auto-injector syringes valued at $1,594.16 with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xolair (omalizumab) 300 mg/2 mL auto-injector vials valued at $3,188.32 under a firm fixed-price contract. The delivery order, issued on August 6, 2025, with a completion date of August 27, 2025, represents a non-competitively set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xolair 300 mg/2 ml auto-injector doses with a ceiling value of $1,594.16 and a firm fixed price arrangement. The contract, which represents a non-set-aside, competitively awarded procurement, is scheduled for ultimate completion by August 26, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical...